Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aponermin - Beijing Sunbio Biotech

Next Previous
Drug Profile

Aponermin - Beijing Sunbio Biotech

Alternative Names: Circularly Permuted TRAIL - Beijing Sunbio Biotech; CPT - Beijing Sunbio Biotech; Human recombinant Apo2L/TRAIL - Beijing Sunbio Biotech; Human recombinant circularly permuted TRAIL - Beijing Sunbio Biotech; Human recombinant CPT - Beijing Sunbio Biotech; Recombinant Apo2L - Beijing Sunbio Biotech; Shaite

Latest Information Update: 04 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Beijing Sunbio Biotech
  • Class Antineoplastics; Immunotherapies; Recombinant proteins
  • Mechanism of Action TRAIL receptor 1 agonists; TRAIL receptor 2 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Multiple myeloma
  • No development reported Solid tumours

Most Recent Events

  • 31 Jan 2025 Institute of Hematology & Blood Diseases Hospital initiates a phase II trial in Multiple myeloma (Combination therapy, Second line therapy or greater) in China (IV, Infusion) (NCT06793475)
  • 02 Nov 2023 Beijing Sunbio Biotech has patent protection for aponermin and its related core technologies in many undisclosed countries worldwide
  • 02 Nov 2023 Registered for Multiple myeloma (Combination therapy, Second-line therapy or greater) in China (IV) - First global approval

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top